Bli medlem
Bli medlem

Du är här


Herantis Pharma Oyj: Herantis Pharma plc shares subscribed with option rights

Herantis Pharma plc shares subscribed with option rights

Herantis Pharma plc.
Stock exchange release 25 September 2015, 9:00 am

18,200 new shares of Herantis Pharma plc. have been subscribed with option
rights of the option programs 2010 and 2014. New shares have been registered
into the Trade Register on 24 September 2015, as of which date the new shares
will establish shareholder rights.

The share capital will not increase with subscriptions. The entire
subscription price of EUR 0.91 will be entered in the invested unrestricted
equity reserve of the company. As a result of the share subscriptions, the
number of shares of Herantis Pharma plc. will increase to 4,085,994 shares.

The new shares will be traded on the NASDAQ OMX Helsinki Ltd's First North
marketplace together with the old shares as of today, 25 September 2015.

Share information of the Herantis Pharma plc. share after the registration of
new shares:

Trading Code: HRTIS
ISIN code: FI4000087861
List: First North Helsinki
Industry: Health Care
Number of Shares: 4,085,994
Share Capital: 80,000.00 euro

Herantis Pharma plc.
Pekka Simula

Further information:

Herantis Pharma plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web

Certified Advisor: UB Securities Ltd, telephone: +358 9 2538 0254

About Herantis Pharma plc.

Herantis Pharma Plc. is a pharmaceutical company specialised in new drug
research and development. The company focuses on diseases with an unmet
clinical need. These diseases include for example dry eye syndrome,
Parkinson's disease, and secondary lymphedema. We believe our drugs are the
first or best in their class and have the potential to change treatment
strategies of diseases. The shares of Herantis Pharma Plc. are listed on the
First North Finland marketplace run by NASDAQ Helsinki stock exchange.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.